The FDA cleared C2N Diagnostics' PrecivityAD2 blood test on August 19, 2026, through its 510(k) pathway, and the clearance extends its labeled use down to adults as young as 40 who have signs of cognitive impairment (FDA's 510(k) database). That makes it the first FDA-cleared Alzheimer's blood test reaching an age floor low enough to matter for younger-onset Alzheimer's, which typically strikes before age 65 (C2N Diagnostics). The test does not diagnose Alzheimer's disease on its own. It estimates the odds that amyloid plaque, a hallmark protein buildup linked to Alzheimer's, is present in the brain, and it is meant to work alongside a clinician's full evaluation, not in place of one.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Explore the official data from FDA — Use this primary source to review the underlying data.
- Read the official guidance from Practicalneurology — Use this primary source to verify the official guidance.
Table of Contents
- What PrecivityAD2 Actually Measures
- Who Is This Test Actually For?
- How Accurate Is a Positive or Negative Result?
- Why the Evidence Is Thinner for Younger Patients
- When Can You Actually Get This Test?
- Frequently Asked Questions
What PrecivityAD2 Actually Measures
PrecivityAD2 is a blood test that uses high-resolution mass spectrometry, a lab technique that identifies and measures molecules by their mass, to measure two types of proteins: beta-amyloid and tau peptide isoforms. The lab combines these measurements into a single amyloid probability score, a number reflecting how likely it is that a person's brain has the amyloid plaque buildup associated with Alzheimer's disease (Practical Neurology).
That score is a probability, not a yes-or-no diagnosis. A clinician still has to weigh it against a patient's symptoms, cognitive testing, and other clinical findings before reaching any conclusion about what's causing a person's cognitive decline. The FDA cleared PrecivityAD2 through the 510(k) pathway, a route the agency uses when a new device is substantially equivalent to one already on the market, rather than the De Novo pathway used for devices with no prior equivalent (FDA).
Who Is This Test Actually For?
The cleared labeling covers adults aged 40 and older who already have signs or symptoms of cognitive impairment and are being evaluated for Alzheimer's disease or another cause of cognitive decline (C2N Diagnostics). That distinction matters: the test is built for people already showing symptoms, not for healthy adults who want to check their risk ahead of time. The labeling explicitly states that PrecivityAD2 is not a screening test and not a standalone diagnostic test.
It's designed to be used together with a clinical assessment, meaning a doctor's evaluation of symptoms, history, and other findings (C2N Diagnostics). For families dealing with younger-onset Alzheimer's, where symptoms appear before age 65, this is the first time a blood test's own FDA clearance has reached into that age range. Before this clearance, blood-based testing options for someone in their 40s or early 50s showing cognitive symptoms were far more limited.
How Accurate Is a Positive or Negative Result?
In a clinical validation study of 1,142 people, a positive PrecivityAD2 result carried a 97.6% positive predictive value for amyloid pathology, meaning that out of everyone who tested positive, 97.6% actually had the amyloid buildup when checked against amyloid PET scans or spinal fluid testing. A negative result carried a 93.1% negative predictive value, meaning most people who tested negative truly did not have amyloid pathology (C2N Diagnostics, cited by Healio). Those numbers only tell part of the story.
The same validation study found that 17.3% of participants received a "likely positive" result, an intermediate or gray-zone outcome rather than a clear positive or negative. For that group, the positive predictive value dropped to 77.3% (Alzheimer's Drug Discovery Foundation). In practical terms, roughly one in six people tested will land in that less certain middle category. A family reading a "likely positive" result should understand it as meaningfully less conclusive than the headline accuracy figures suggest, and worth discussing directly with the ordering clinician about what additional testing, such as a PET scan, might still be needed.
Why the Evidence Is Thinner for Younger Patients
C2N didn't start at age 40. The company's earlier lab-developed version of PrecivityAD2 launched restricted to adults 60 and older, was expanded to 50 and older in August 2025, and only reached down to 40 and older with this August 2026 FDA clearance (C2N Diagnostics). That staged rollout means the clinical evidence behind using the test on someone in their 40s is the newest and least extensively accumulated part of the test's track record, compared with the data built up over several years for older age groups.
For a family facing possible younger-onset Alzheimer's, that's a reasonable thing to ask a clinician about directly: how the test's performance in this validation applies specifically to a patient in their 40s versus the broader study population. Independent reporting places PrecivityAD2 as the third FDA-cleared blood-based Alzheimer's biomarker test to reach the market, following Fujirebio's Lumipulse plasma assay. Both tests trace back to early research funding from the Alzheimer's Drug Discovery Foundation (ADDF). Having a second cleared option on the market gives clinicians a point of comparison, but it doesn't change the fact that younger-patient data for either test remains more limited than data for patients over 60.
When Can You Actually Get This Test?
C2N says the newly FDA-cleared version of PrecivityAD2 is expected to become commercially available later in 2026. Until that rolls out, only the earlier CLIA-validated version, a laboratory-developed test validated under federal lab-certification standards rather than FDA clearance, remains orderable through C2N's own laboratory (C2N Diagnostics). Anyone considering the test for a younger family member showing cognitive symptoms should ask their doctor which version is being ordered and whether it carries the FDA-cleared labeling or the earlier lab-developed designation, since the two have been validated through different pathways.
Frequently Asked Questions
Does a positive PrecivityAD2 result mean a person has Alzheimer's disease?
No. It means amyloid pathology is likely present in the brain; a clinician still has to combine that with symptoms, cognitive testing, and other findings to reach a diagnosis (C2N Diagnostics).
Can a healthy 45-year-old with no symptoms request this test to check their risk?
The cleared labeling covers adults 40 and older who already have signs or symptoms of cognitive impairment under evaluation; it is explicitly not a screening test for people without symptoms (C2N Diagnostics).
What happens if a result comes back "likely positive" instead of a clear positive or negative?
That gray-zone result occurred in 17.3% of the validation study's participants and carries a lower, 77.3% positive predictive value, so it typically calls for further discussion with the ordering clinician about additional testing (Alzheimer's Drug Discovery Foundation).
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Questions Younger-Onset Alzheimer’s Families Can Bring to a Clinician
- The HHS National Alzheimer’s Plan Update for 2026-2035: Eligibility and Participation Questions for Adult Children
- Young-Onset Dementia Cost Gaps Identified by NIA in 2026: What the Report Means for Working Dementia Caregivers
